Where life-changing innovation meet real-world solutions

King’s Innovation Catalyst is the first point of contact for investors interested in licensing our technologies and investing in our spinout opportunities.

As one of the UK’s leading research-intensive universities, King’s College London has a dynamic portfolio of available technologies and a track record of spinout successes to discover.

Under King's College London's equity stake framework, academic founders retain between 85% and 100% ownership of their spinout at formation. 

"By empowering researchers to play a leading role in the commercial success of their innovations, we can maximise the economic and societal impact of discoveries emerging from King's." - Professor Sebastien Ourselin, FREng FMedSci

Under the framework, the university's equity stake varies according to the type and intensity of the intellectual property (IP) being commercialised:

• 0% equity for social ventures, including impact-focused and not-for-profit organisations.
• 5% equity for non-patentable software and digital ventures, including software products, digital platforms and copyright-based innovations.
• 10% equity for patentable non-pharmaceutical technologies, such as engineering innovations, medical technologies, robotics and advanced materials.
• 15% equity for pharmaceutical technologies, including therapeutics, biotechnology and drug development.

To learn more about the equity stake framework, see the announcement in King's news.